share_log

Panbela Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Panbela Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Panbela Therapeutics | PRE 14A：並購重組委托聲明
美股sec公告 ·  03/25 16:22
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in 2024, with the exact date yet to be determined. The meeting will address two key proposals: a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, and the potential adjournment of the meeting if necessary to solicit additional proxies. Stockholders of record as of March 27, 2024, will be eligible to vote. The reverse stock split aims to increase the per-share market price of Panbela's common stock to meet national securities exchange listing requirements and avoid penny stock classification. This follows the Nasdaq Hearings Panel's decision to delist Panbela's common stock, which was suspended from trading on March 7, 2024, and is now quoted on the OTC Pink market. The Board of Directors has unanimously approved the proposals and recommends stockholders vote in favor. The proposals are detailed in the proxy statement, which will be distributed starting on or about the date of the announcement.
Panbela Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in 2024, with the exact date yet to be determined. The meeting will address two key proposals: a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, and the potential adjournment of the meeting if necessary to solicit additional proxies. Stockholders of record as of March 27, 2024, will be eligible to vote. The reverse stock split aims to increase the per-share market price of Panbela's common stock to meet national securities exchange listing requirements and avoid penny stock classification. This follows the Nasdaq Hearings Panel's decision to delist Panbela's common stock, which was suspended from trading on March 7, 2024, and is now quoted on the OTC Pink market. The Board of Directors has unanimously approved the proposals and recommends stockholders vote in favor. The proposals are detailed in the proxy statement, which will be distributed starting on or about the date of the announcement.
Panbela Therapeutics, Inc.宣佈將在2024年虛擬舉行股東特別會議，具體日期尚未確定。會議將討論兩項關鍵提案：以1比10和1比45的比例反向拆分公司普通股，以及在必要時可能休會以尋求更多代理人。截至2024年3月27日的登記股東將有資格投票。反向股票拆分旨在提高Panbela普通股的每股市場價格，以滿足國家證券交易所的上市要求並避免細價股的分類。在此之前，納斯達克聽證會小組決定將Panbela的普通股退市，該普通股於2024年3月7日暫停交易，現已在場外粉紅市場上市。董事會一致批准了這些提案，並建議股東投贊成票。委託書中詳細介紹了這些提案，委託書將在公告發布之日或前後分發。
Panbela Therapeutics, Inc.宣佈將在2024年虛擬舉行股東特別會議，具體日期尚未確定。會議將討論兩項關鍵提案：以1比10和1比45的比例反向拆分公司普通股，以及在必要時可能休會以尋求更多代理人。截至2024年3月27日的登記股東將有資格投票。反向股票拆分旨在提高Panbela普通股的每股市場價格，以滿足國家證券交易所的上市要求並避免細價股的分類。在此之前，納斯達克聽證會小組決定將Panbela的普通股退市，該普通股於2024年3月7日暫停交易，現已在場外粉紅市場上市。董事會一致批准了這些提案，並建議股東投贊成票。委託書中詳細介紹了這些提案，委託書將在公告發布之日或前後分發。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息